Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2025-2033
상품코드:1820085
리서치사:IMARC
발행일:2025년 09월
페이지 정보:영문 146 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 림프종 치료 시장 규모는 2024년 143억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 274억 달러에 달하고, 2025년부터 2033년까지 7.13%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 치료 방법의 발전, 림프종 발병률 증가, 의료비 지출 급증, 지속적인 기술 혁신이 시장 성장을 주도하고 있습니다.
림프종 치료 시장 동향:
림프종 유병률 증가
호지킨림프종과 비호지킨림프종을 포함한 림프종 유병률은 인구 고령화와 진단 능력 향상 등의 요인으로 인해 전 세계적으로 증가하고 있습니다. 예를 들어, 미국암협회에 따르면 2024년에는 약 80,000명이 비호지킨림프종에 걸릴 것으로 예상하고 있습니다. 따라서 효율적인 치료에 대한 수요가 더욱 증가하여 향후 몇 년 동안 림프종 치료 시장의 원동력이 될 것으로 예측됩니다.
맞춤형 의료에 대한 관심 증가
맞춤형 의료에 대한 관심이 높아지면서 림프종 치료 시장의 성장에 큰 힘이 되고 있습니다. 예를 들어, IMARC에 따르면, 세계 정밀의료 시장 규모는 2023년 752억 달러에 달했습니다. 향후 IMARC Group은 2024년부터 2032년까지 9.1%의 연평균 성장률(CAGR)을 보이며 2032년까지 시장이 1,683억 달러에 달할 것으로 예측했습니다. 림프종 치료의 맞춤의료는 유전자, 분자, 면역학적 프로파일을 포함한 환자 개개인의 특성에 따라 치료법을 조정하는 것을 포함합니다. 이러한 요인들은 림프종 치료 시장 예측에 더욱 긍정적인 영향을 미칠 것입니다.
R&D 투자 증가
제약기업과 연구기관의 연구개발에 대한 막대한 투자는 림프종 치료제의 신규 개발 및 개선을 촉진하고, 혁신적인 치료법으로 시장을 확대하고 있습니다. 예를 들어, 2023년 11월, 혈액암 연구 민간 지원 기관인 Leukemia &Lymphoma Society(LLS)는 7개국 78개 연구팀에 6,500만 달러의 새로운 상금을 수여했습니다. 또한, 현재 진행 중인 임상시험 및 조사 연구는 치료법의 발전과 새로운 치료법 시장 도입에 기여하여 림프종 치료 시장의 수익을 증대시키고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
조사 목적
이해관계자
데이터 소스
1차 정보
2차 정보
시장 추정
상향식 접근
하향식 접근
조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 림프종 치료 시장
시장 개요
시장 실적
COVID-19의 영향
시장 예측
제6장 시장 내역 : 유형별
호지킨림프종
비호지킨림프종
제7장 시장 내역 : 검사 유형별
화학요법
방사선 치료
면역요법
표적요법
생물학적요법
기타
제8장 시장 내역 : 약제별
Adcetris
Rituxan
Opdivo
Imbruvica
Keytruda
Revlimid
기타
제9장 시장 내역 : 지역별
북미
미국
캐나다
아시아태평양
중국
일본
인도
한국
호주
인도네시아
기타
유럽
독일
프랑스
영국
이탈리아
스페인
러시아
기타
라틴아메리카
브라질
멕시코
기타
중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
시장 구조
주요 기업
주요 기업 개요
Abbott Laboratories
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Merck & Co. Inc.
Novartis International AG
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
KSM
영문 목차
영문목차
The global lymphoma treatment market size reached USD 14.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The rising advancements in treatment modalities, increasing incidence of lymphoma, surging healthcare expenditure, and ongoing technological innovations are primarily driving the market's growth.
Lymphoma Treatment Market Trends:
Rising Prevalence of Lymphoma
The prevalence of lymphoma, including both Hodgkin and non-Hodgkin lymphoma, is rising globally due to factors like aging populations and improved diagnostic capabilities. For instance, according to the American Cancer Society, nearly 80,000 people will suffer from non-Hodgkin lymphoma in 2024. This further drives the demand for efficient treatment, further expected to propel the lymphoma treatment market in the coming years.
Surging Focus on Personalized Medicine
The rising focus on personalized medicine is significantly driving growth in the lymphoma treatment market. For instance, according to IMARC, the global precision medicine market size reached US$ 75.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 168.3 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032. Personalized medicine in lymphoma treatment involves tailoring therapies based on individual patient characteristics, including genetic, molecular, and immunological profiles. These factors further positively influence the lymphoma treatment market forecast.
Increasing R&D Investments
Significant investments in R&D by pharmaceutical companies and research institutions drive the development of new and improved lymphoma treatments, expanding the market with innovative therapies. For instance, in November 2023, the Leukemia & Lymphoma Society (LLS), a private supporter of blood cancer research, granted $65 million in new awards to 78 research teams in seven countries. Moreover, ongoing clinical trials and research studies contribute to the advancement of treatment options and the introduction of novel therapies to the market, thereby boosting the lymphoma treatment market revenue.
Global Lymphoma Treatment Industry Segmentation:
Breakup by Type:
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
According to the lymphoma treatment market outlook, Hodgkin lymphoma comprises a smaller proportion of all lymphomas, accounting for approximately 10% of cases worldwide. Moreover, it is more prevalent in developed countries compared to developing regions. Moreover, non-Hodgkin lymphoma is more common than Hodgkin lymphoma, accounting for approximately 90% of all lymphoma cases globally. NHL incidence rates have been increasing over the past few decades.
Breakup by Test Type:
Chemotherapy
Radiation Therapy
Immunotherapy
Targeted Therapy
Biologic Therapy
Others
According to the lymphoma treatment market overview, chemotherapy involves the use of drugs to kill cancer cells or slow their growth. These drugs can be administered orally or intravenously and work by targeting rapidly dividing cells throughout the body. Moreover, radiation therapy uses high-energy beams to target and destroy cancer cells. It is often delivered externally (external beam radiation) or internally (brachytherapy). Apart from this, immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Key approaches include monoclonal antibodies and immune checkpoint inhibitors.
Breakup by Drug:
Adcetris
Rituxan
Opdivo
Imbruvica
Keytruda
Revlimid
Others
Adcetris is primarily used for the treatment of Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphoma (NHL), such as systemic anaplastic large cell lymphoma (sALCL). Moreover, Rituxan is a monoclonal antibody targeting CD20 antigen primarily used in B-cell NHL and certain autoimmune diseases like rheumatoid arthritis. Apart from this, Opdivo is an immune checkpoint inhibitor targeting PD-1 receptor used in various cancers, including melanoma, lung cancer, and Hodgkin lymphoma.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
According to the lymphoma treatment market statistics, North America represents a significant portion of the global lymphoma treatment market owing to the higher prevalence of lymphoma, particularly non-Hodgkin lymphoma (NHL), due to factors like aging population and environmental exposures. Moreover, the increasing emphasis on genomic profiling and targeted therapies, is driving the market growth in Europe. Apart from this, the rising incidence of lymphoma in Asia Pacific, partly due to aging populations, urbanization, and changing lifestyles is supporting the industry's demand.
Competitive Landscape:
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
Abbott Laboratories
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis International AG
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global lymphoma treatment market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the drug?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global lymphoma treatment market and who are the key players?
What is the degree of competition in the industry?
